RCT-2100 is under clinical development by Recode Therapeutics and currently in Phase II for Cystic Fibrosis. According to GlobalData, Phase II drugs for Cystic Fibrosis have a 31% phase transition ...

Galicaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.

Cystic fibrosis is a genetic disorder that affects various organs, including the lungs and digestive system. Medications are important for managing symptoms, but there is currently no cure for the ...

A connection between lung health and kidney function in adults with cystic fibrosis (CF), identifying early urinary markers ...

(MENAFN- EIN Presswire) Numerous companies, such as Vertex Pharmaceuticals, Eloxx Pharmaceuticals, and others, are actively developing treatments in the Cystic Fibrosis market. LAS VEGAS ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...

Biomarker staging of liver fibrosis in hepatitis C was cost effective, but so was initiating treatment without testing.